ZTS

Zoetis Inc.

HealthcareDrug Manufacturers - Specialty & GenericNASDAQ

$77.69

-$2.31 (-2.97%)today

Conviction

0/ 10

Fair Value$151

Upside+94.36%

Signal0

Market Cap$51.7B

52W Range$113.29–$172.23

Next EarningsMay 7

Price History

FAIR VALUE ANALYSISMonte Carlo · 3,000 runs · 99% valid

Fair Value$77.66

Current Price$118.15

Upside / Down-34.3%

P(Undervalued)0.8%

P(20%+ Up)0.0%

P(15%+ Down)90.8%

Fair Value Distribution — percentile bands

0.8% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

12.7%/yr

±4.1% · revenue growth to justify current price

FCF-Based Reverse DCF

12.8%/yr

±3.0% · FCF growth to justify current price

THE GAP

Market pricing margin compression or rising capex

Premium Content

Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.

Quick Take

Zoetis Inc.

Trailing P/E19.5x

Forward P/E15.5x

P/S5.5x

EPS (TTM)$6.01

Analyst Target$151

Analyst Upside94.4%

No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kMar 2

Conviction: unchanged

ZTS 2025 10-K: Diversified Growth Platform with Patent Headwinds

Zoetis 2025 revenue .35B (U.S. 54%, Intl 45%). Patent cliff 2025-27 (Draxxin, Cerenia), dependent on lifecycle innovation fill. R&D up 2% to M. Companion animals 70% of revenue (resilient); livestock ...